Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Flu Vaccine: Recent Supply Shortages Underscore Ongoing Challenges
- Influenza is associated with an average of 36,000 deaths and more than 200,000 hospitalizations each year in the United States. Persons who are aged 65 and older, people with chronic medical conditions, children younger than 2 years, and pregnant women are more likely to get severe complications from influenza than...
- White papers 2004-11-18
Additional Resources
- Medicago's H5N1 VLP Vaccine Demonstrates Cross-Reactivity Against Multiple Strains of Avian Flu in Key Ferret Animal Model
- Medicago Inc. (TSX VENTURE: MDG) today announced additional positive results for the Company's H5N1 Avian Influenza VLP vaccine from a preclinical immunogenicity study performed in ferrets, the most predictive animal model for evaluating the effectiveness of influenza vaccines in humans. The Company's H5N1 VLP vaccine induced high levels of antibodies...
- Articles 2008-06-25
- VGX Announces Publication of Preclinical Data for the Company's Avian Flu Vaccine Candidate in PLoS ONE Journal
- BLUE BELL, Pa. -- VGX Pharmaceuticals Inc. VGX announced today the publication in PLoS ONE - an international, peer-reviewed, open-access, online publication - of preclinical data for the Company's preventative DNA vaccine candidate for avian influenza, VGX-3400. The article, titled "Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via...
- Articles 2008-06-25
- U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel®
- - PentacelR vaccine is the first 5-in-1 pediatric combination for immunization against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b Hib - SWIFTWATER, Pa. and LYON, France, June 23 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food...
- Articles 2008-06-23
- Vical Pandemic Influenza Vaccines Provide Complete Protection in Animal Studies; The Journal of Infectious Diseases Publishes H5N1 Challenge Data
- SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Vical Incorporated announced today the publication of results demonstrating that pandemic influenza DNA vaccines formulated with the company's patented VaxfectinR adjuvant provided complete protection of mice and ferrets against lethal challenge with a highly pathogenic strain of H5N1 influenza virus. The publication...
- Articles 2008-06-16
- Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
- LYON, France and SWIFTWATER, Pa., June 16 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today its commitment to donate 60 million doses of H5N1 vaccine to the World Health Organization WHO over 3 years for the establishment of an H5N1 vaccine global stockpile. ...
- Articles 2008-06-16
- VaxInnate to Discuss Seasonal and Pandemic Flu Vaccines During BIO 2008 This Week
- Company's Novel Vaccine Technology Could Revolutionize Production of Flu Vaccines With Enhanced Potency, Manufacturing Capacity and Cost-Effectiveness SAN DIEGO -- VaxInnate Corporation announced today that it will discuss its novel proprietary technology for producing seasonal and pandemic influenza vaccines during BIO 2008 here this week. VaxInnate...
- Articles 2008-06-16
- Importance of vaccinations for close contacts and caregivers
- TO THE EDITOR: Drs. LaHood and Bryant should be commended for outlining the need for vigilant health care screening of the premature infant, especially for emphasizing the importance of influenza vaccinations for close contacts and caregivers, who can serve as reservoirs and agents of disease transmission. However, two...
- Articles 2008-06-15
- Stimulation of Lung Innate Immunity Protects against Lethal Pneumococcal Pneumonia in Mice
- Rationale: The lungs are a common site of serious infection in both healthy and immunocompromised subjects, and the most likely route of delivery of a bioterror agent. Since the airway epithelium shows great structural plasticity in response to inflammatory stimuli, we hypothesized it might also show functional plasticity. Objectives:...
- Articles 2008-06-15
- Emergency Filtration Products Submits 510(k) Pre-Market Notification to FDA for NanoMask
- Emergency Filtration Products, Inc. EFP(PINKSHEETS: EMFP) announced that earlier today it had filed a 510kpre-market notification with the U.S. Food and Drug Administration FDAfor its NanoMaskTM. The process, timing and results of any FDA submissionwill be determined solely by the FDA, though the company has requested anexpedited review pursuant to...
- Articles 2008-06-13
- Lax quarantine blamed for Australian equine flu outbreak
- SYDNEY AFP — An equine influenza outbreak that crippled the Australian horse racing industry was started by animals from Japan and spread through lax quarantine practices, an official report found Thursday. The outbreak shut down Australian racing in many states for months in late 2007, a crisis the...
- Articles 2008-06-12
- US life expectancy reaches 78 for the first time
- WASHINGTON AFP — The average life expectancy in the United States reached 78 years for the first time in 2006, according to government figures. The figures also show a clear drop in the number of Americans killed by eight of the 10 leading causes of death. ...
- Articles 2008-06-11
- The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine
- First scientific, peer-reviewed publication showing the candidate vaccine induced neutralizing antibodies against widely divergent H5N1 virus DEERFIELD, Ill., June 11 /PRNewswire-FirstCall/ -- Baxter International Inc. announced publication in the June 12, 2008 issue of The New England Journal of Medicine NEJM of data demonstrating Baxter's candidate...
- Articles 2008-06-11
- Ambrilia Unveils its Complete Antivirals Portfolio and Highlights Progress Made in the Strategic Plan Execution
- Ambrilia Biopharma Inc. (TSX: AMB) today unveiled during its Annual General Meeting its complete antivirals portfolio comprising of small molecules and peptides targeting HIV/AIDS, Hepatitis C and Influenza A, as well as highlighted the latest progress made in the strategic plan execution. "Important strides were made recently and now Ambrilia...
- Articles 2008-06-10
- Cerus Announces INTERCEPT Blood System Data Presented at International Society of Blood Transfusion Conference Support Broad Utility in Safeguarding the Blood Supply
- Results from 32 Studies Highlight the INTERCEPT Blood System's Ability to Improve the Safety of Donated Blood by Inactivating Viruses, Bacteria, Protozoa and Leukocytes CONCORD, Calif. -- Cerus Corporation (NASDAQ:CERS) announced today results from 32 studies on the INTERCEPT Blood System presented at the International Congress of the...
- Articles 2008-06-09
- Nanogen Awarded New CDC Contract to Develop Molecular Diagnostic Test for Influenza and Avian Flu
- SAN DIEGO -- Nanogen, Inc. (Nasdaq: NGEN), developer of in vitro diagnostic products, announced today it has been awarded a new $10.4 million, two-year contract from the U.S. Centers for Disease Control and Prevention CDC to develop a multi-analyte molecular diagnostic assay for Influenza. This new contract will have Nanogen...
- Articles 2008-06-05
- Bioject and ImmunoVaccine Technologies Announce Research Collaboration
- Researchers Explore Possibility of Enhancing Delivery of Pandemic Flu Vaccine PORTLAND, Ore. & HALIFAX, Nova Scotia -- Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free injection therapy NFIT systems, and ImmunoVaccine Technologies, Inc. IVT, a vaccine development company, today announced they have entered into a...
- Articles 2008-06-05
- Medicago's H5N1 Pandemic Flu Vaccine Effective in Key Ferret Animal Model With Single Dose
- Medicago Inc. (TSX VENTURE: MDG) today announced positive results from a preclinical immunogenicity study of the Company's H5N1 Avian Influenza VLP vaccine that was performed in ferrets, the most predictive animal model for the effectiveness of influenza vaccines in humans. Results demonstrated that a single 5-microgram dose of the Company's...
- Articles 2008-06-03
- The Aethlon Hemopurifier® Proves Effective in Capturing the Reconstructed Spanish Flu of 1918 and H5N1 Avian Influenza Virus
- SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that the Aethlon Hemopurifier([R])has proven effective in capturing the reconstructed Spanish Flu of 1918 virus (1918rv). During in vitro testing, high concentrations of 1918rv were rapidly depleted from cell culture fluid when circulated through the Hemopurifier[R]. The study documented that 76...
- Articles 2008-06-03
- Banner Pharmacaps Receives FDA Approval for Amantadine Softgel Capsules
- HIGH POINT, N.C. -- Banner Pharmacaps Inc., a leader in the pharmaceutical industry for the development of soft gelatin dosage form technology, announces that the US Food & Drug Administration granted approval for the Company's Abbreviated New Drug Application ANDA for Amantadine Hydrochloride USP 100 mg soft gelatin capsules on...
- Articles 2008-06-02
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
- Dell: Built to fit your business needs.
-
Powerful, Dell is built to fit your business needs Customized systems, experts trained in small business, 24/7/365 support, and powerful, reliable technology. Dell, big results for small business.
- Learn More >>
- THE FUTURE JUST LOST ITS LEAD.
-
We're relentless about invention. Our latest technology includes hafnium-based circuitry, mobile technology for a new generation of MIDs, and 32 nanometer processing.
- Learn more >>
- Technology Innovation
-
Discover how Intel is advancing the pace of new developments in architecture and silicon and delivering great leaps in energy efficiency and processor performance.
- Transform your computing experience >>


